biote Corp.(BTMD)Earnings, Financials & Key Ratios

BTMD•NASDAQ

$2.09

$92M mkt cap·2.8× P/E·Price updated May 7, 2026

SectorHealthcare IndustryHealthcare Facilities Sub-IndustryPhysician platforms and value-based care

Aboutbiote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.Show more

Revenue$192M-2.5%
EBITDA$39M+11.5%
Net Income$27M+756.7%
EPS (Diluted)0.74+703.5%
Gross Margin71.46%+1.3%
EBITDA Margin20.4%+14.4%
Operating Margin18.5%+15.4%
Net Margin14.07%+778.8%
ROIC1129.32%
Interest Coverage3.24+196.9%

Technical→

BTMD Key Insights

biote Corp. (BTMD) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓FCF machine: 15.7% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 10.5%
✓Healthy dividend yield of 2.3%
✓Efficient asset utilization: 1.8x turnover

✗Weaknesses

✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

BTMD Price & Volume

biote Corp. (BTMD) stock price & volume — 10-year historical chart

Loading chart...

BTMD Growth Metrics

biote Corp. (BTMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years10.52%

3 Years5.23%

TTM-5.63%

Profit CAGR

10 Years-

5 Years-1.5%

3 Years-

TTM-28.43%

EPS CAGR

10 Years-

5 Years-28.1%

3 Years66.61%

TTM-27.23%

Return on Capital

10 Years80.8%

5 Years27.11%

3 Years36.54%

Last Year53.27%

BTMD Recent Earnings

biote Corp. (BTMD) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 10/12 qtrs (83%)●Beat Revenue 7/12 qtrs (58%)

Q2 2026Latest

May 6, 2026

EPS

$0.06

Est $0.09

-33.3%

Revenue

$45M

Est $46M

-2.4%

Q2 2026

Mar 11, 2026

EPS

$0.06

Est $0.05

+20.0%

Revenue

$46M

Est $46M

+1.3%

Q4 2025

Nov 5, 2025

EPS

$0.22

Est $0.05

+340.0%

Revenue

$48M

Est $46M

+4.7%

Q3 2025

Aug 6, 2025

EPS

$0.10

Est $0.06

+66.7%

Revenue

$49M

Est $48M

+2.3%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 6, 2026	$0.06vs $0.09-33.3%	$45Mvs $46M-2.4%
Q2 2026	Mar 11, 2026	$0.06vs $0.05+20.0%	$46Mvs $46M+1.3%
Q4 2025	Nov 5, 2025	$0.22vs $0.05+340.0%	$48Mvs $46M+4.7%
Q3 2025	Aug 6, 2025	$0.10vs $0.06+66.7%	$49Mvs $48M+2.3%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
HIMSHims & Hers Health, Inc.Direct Competitor	6.63B	25.67	50.32	59%	5.47%	23.73%	2.07
EVAXEvaxion Biotech A/SDirect Competitor	25.71M	4.07	-3.36	125.81%	-102.38%	-61.62%	0.44
AMWLAmerican Well CorporationDirect Competitor	129.49M	7.75	-1.30	-1.98%	-48.16%	-33.48%	0.02
NUVBNuvation Bio Inc.Direct Competitor	1.67B	4.82	-8.03	6.99%	-102.06%	-44.1%	0.03
GDRXGoodRx Holdings, Inc.Direct Competitor	973.26M	2.84	33.29	0.57%	3.74%	4.75%	0.10
DOCSDoximity, Inc.Direct Competitor	5.24B	26.03	23.45	19.98%	37.54%	24.45%	0.01
ABBVAbbVie Inc.Product Competitor	358.42B	202.64	85.50	8.57%	6.91%	62.15%
AVDLAvadel Pharmaceuticals plcProduct Competitor	2.1B	21.64	-42.43	5.05%	-0.11%	-0.33%	0.02

Compare BTMD vs Peers

biote Corp. (BTMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs HIMS

Most directly comparable listed peer for BTMD.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare BTMD against a more recognizable public peer.

Peer Set

Compare Top 5

vs HIMS, EVAX, AMWL, NUVB

BTMD Income Statement

biote Corp. (BTMD) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	109.98M	116.57M	139.4M	164.96M	185.36M	197.19M	192.22M	188.16M
Revenue Growth %	-	5.99%	19.58%	18.34%	12.37%	6.38%	-2.52%	-5.63%
Cost of Goods Sold	43.56M	44.93M	48.82M	54.58M	57.88M	58.13M	54.86M	56.23M
COGS % of Revenue	39.61%	38.54%	35.02%	33.08%	31.22%	29.48%	28.54%	-
Gross Profit	66.41M▲ 0%	71.64M▲ 7.9%	90.58M▲ 26.4%	110.38M▲ 21.9%	127.48M▲ 15.5%	139.06M▲ 9.1%	137.36M▼ 1.2%	131.93M▲ 0%
Gross Margin %	60.39%	61.46%	64.98%	66.92%	68.78%	70.52%	71.46%	70.12%
Gross Profit Growth %	-	7.87%	26.44%	21.86%	15.49%	9.08%	-1.22%	-
Operating Expenses	42.88M	39.86M	56.02M	171.1M	98.83M	107.45M	101.81M	102.91M
OpEx % of Revenue	38.99%	34.19%	40.19%	103.73%	53.32%	54.49%	52.97%	-
Selling, General & Admin	39.29M	37.43M	53.96M	171.1M	0	107.45M	101.81M	102.91M
SG&A % of Revenue	35.73%	32.11%	38.71%	103.73%	-	54.49%	52.97%	-
Research & Development	0	0	0	0	0	0	0	0
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	3.59M	2.43M	2.06M	0	98.83M	0	0	0
Operating Income	23.53M▲ 0%	31.78M▲ 35.1%	34.56M▲ 8.7%	-60.72M▼ 275.7%	28.66M▲ 147.2%	31.61M▲ 10.3%	35.55M▲ 12.5%	29.03M▲ 0%
Operating Margin %	21.39%	27.26%	24.79%	-36.81%	15.46%	16.03%	18.5%	15.43%
Operating Income Growth %	-	35.08%	8.75%	-275.7%	147.19%	10.31%	12.46%	-
EBITDA	24.36M	32.92M	35.96M	-58.52M	29.45M	35.19M	39.22M	31.84M
EBITDA Margin %	22.15%	28.24%	25.8%	-35.48%	15.89%	17.84%	20.4%	16.92%
EBITDA Growth %	-	35.14%	9.24%	-262.74%	150.32%	19.47%	11.47%	-6.78%
D&A (Non-Cash Add-back)	832K	1.14M	1.4M	2.2M	794K	3.57M	3.67M	2.81M
EBIT	23.46M	31.78M	34.58M	5.76M	38.74M	12.02M	35.55M	18.36M
Net Interest Income	-2.08M	-2.42M	-1.67M	-4.05M	-6.36M	-11M	-10.96M	-8.06M
Interest Income	0	0	0	0	0	0	0	0
Interest Expense	2.08M	2.42M	1.67M	4.05M	6.36M	11M	10.96M	6.08M
Other Income/Expense	-2.15M	-2.43M	-1.66M	62.43M	-28.78M	-30.59M	2.03M	-5.56M
Pretax Income	21.38M▲ 0%	29.35M▲ 37.3%	32.91M▲ 12.1%	1.71M▼ 94.8%	-123K▼ 107.2%	1.02M▲ 926.0%	37.58M▲ 3599.2%	23.47M▲ 0%
Pretax Margin %	19.44%	25.18%	23.61%	1.04%	-0.07%	0.52%	19.55%	12.47%
Income Tax	93K	189K	286K	388K	2.68M	970K	5.99M	5.03M
Effective Tax Rate %	0.43%	0.64%	0.87%	22.66%	-2180.49%	95.47%	15.93%	21.45%
Net Income	21.29M▲ 0%	29.16M▲ 37.0%	32.62M▲ 11.9%	-969K▼ 103.0%	3.32M▲ 442.2%	3.16M▼ 4.8%	27.05M▲ 756.7%	15.6M▲ 0%
Net Margin %	19.36%	25.02%	23.4%	-0.59%	1.79%	1.6%	14.07%	8.29%
Net Income Growth %	-	36.99%	11.85%	-102.97%	442.21%	-4.79%	756.67%	-28.43%
Net Income (Continuing)	21.29M	29.16M	32.62M	1.32M	-2.81M	46K	31.6M	18.04M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	-13.81M	-7.15M	3.73M	8.14M	8.14M
EPS (Diluted)	2.81▲ 0%	3.85▲ 37.0%	-0.87▼ 122.6%	0.16▲ 118.4%	0.13▼ 18.8%	0.09▼ 29.2%	0.74▲ 703.5%	0.43▲ 0%
EPS Growth %	-	37.01%	-122.6%	118.39%	-18.75%	-29.15%	703.47%	-27.23%
EPS (Basic)	2.81	3.85	-0.87	0.16	0.13	0.09	0.86	-
Diluted Shares Outstanding	7.57M	7.57M	7.57M	8.06M	25.71M	34.27M	36.67M	36M
Basic Shares Outstanding	7.57M	7.57M	7.57M	8.06M	25.71M	34.27M	31.28M	30.65M
Dividend Payout Ratio	266.05%	45.67%	34.96%	-	262.18%	150.27%	6.39%	-

BTMD Balance Sheet

biote Corp. (BTMD) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	19.3M	27.82M	47.09M	101.18M	122.34M	68.13M	54.67M	36.36M
Cash & Short-Term Investments	10.49M	17.21M	26.77M	79.23M	89M	39.34M	24.12M	5.32M
Cash Only	10.49M	17.21M	26.77M	79.23M	89M	39.34M	24.12M	5.32M
Short-Term Investments	0	0	0	0	0	0	0	0
Accounts Receivable	4.02M	4.72M	5.23M	6.95M	8.17M	7.7M	6.87M	7.4M
Days Sales Outstanding	13.33	14.78	13.7	15.37	16.1	14.26	13.04	15.23
Inventory	3.92M	4.32M	9.62M	11.18M	17.31M	14.85M	19.06M	19.88M
Days Inventory Outstanding	32.82	35.13	71.89	74.79	109.15	93.21	126.84	109.58
Other Current Assets	0	0	3.94M	0	308K	111K	4.62M	3.76M
Total Non-Current Assets	4.59M	4.76M	7.25M	10.47M	32.95M	54.24M	52.94M	52.68M
Property, Plant & Equipment	2.76M	2.17M	2.69M	3.56M	3.1M	10.22M	13.45M	13.26M
Fixed Asset Turnover	39.79x	53.84x	51.80x	46.39x	59.89x	19.30x	14.29x	14.33x
Goodwill	0	0	0	0	0	5.83M	5.83M	5.83M
Intangible Assets	1.82M	2.6M	4.55M	5.07M	4.97M	9.38M	4.27M	9.03M
Long-Term Investments	0	0	0	0	0	0	0	0
Other Non-Current Assets	-4.59M	0	0	0	0	72K	4.6M	4.81M
Total Assets	23.89M▲ 0%	32.59M▲ 36.4%	54.33M▲ 66.7%	111.64M▲ 105.5%	155.29M▲ 39.1%	122.37M▼ 21.2%	107.61M▼ 12.1%	89.03M▲ 0%
Asset Turnover	4.60x	3.58x	2.57x	1.48x	1.19x	1.61x	1.79x	1.82x
Asset Growth %	-	36.4%	66.72%	105.49%	39.1%	-21.2%	-12.06%	-17.14%
Total Current Liabilities	13.51M	11.71M	17.31M	18.77M	22.21M	51.51M	44.99M	28.23M
Accounts Payable	3.19M	2.44M	4.35M	4.11M	4.16M	5.81M	6.83M	8.24M
Days Payables Outstanding	26.72	19.86	32.52	27.5	26.2	36.5	45.42	37.79
Short-Term Debt	5M	5M	5M	6.25M	6.25M	6.25M	6.84M	6.86M
Deferred Revenue (Current)	0	2.04M	1.71M	1.97M	3M	2.96M	3.02M	12.08M
Other Current Liabilities	2.58M	1.36M	2.21M	4.22M	6.07M	30.32M	28.31M	10.28M
Current Ratio	1.43x	2.38x	2.72x	5.39x	5.51x	1.32x	1.22x	1.22x
Quick Ratio	1.14x	2.01x	2.16x	4.80x	4.73x	1.03x	0.79x	0.79x
Cash Conversion Cycle	19.43	30.04	53.07	62.66	99.04	70.97	94.47	87.02
Total Non-Current Liabilities	43.31M	37.95M	32.89M	151.15M	169.63M	173.06M	113.02M	108.76M
Long-Term Debt	41.52M	36.74M	31.96M	112.09M	106.63M	101.2M	100.78M	99.42M
Capital Lease Obligations	614K	375K	127K	1.93M	1.68M	2.89M	2.3M	9.49M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	1.17M	0	0	36.21M	59.99M	67.41M	8.84M	65.4M
Total Liabilities	56.82M	49.66M	50.2M	169.92M	191.84M	224.57M	158.01M	136.99M
Total Debt	47.13M	42.35M	37.34M	120.43M	114.87M	110.86M	109.92M	108.42M
Net Debt	36.65M	25.15M	10.57M	41.2M	25.87M	71.52M	85.8M	103.1M
Debt / Equity	-	-	9.05x	-	-	-	-	-2.26x
Debt / EBITDA	1.93x	1.29x	1.04x	-	3.90x	3.15x	2.80x	3.41x
Net Debt / EBITDA	1.50x	0.76x	0.29x	-	0.88x	2.03x	2.19x	2.19x
Interest Coverage	11.27x	13.10x	20.67x	1.42x	6.09x	1.09x	3.24x	3.02x
Total Equity	-32.93M▲ 0%	-17.07M▲ 48.1%	4.13M▲ 124.2%	-58.27M▼ 1512.7%	-36.55M▲ 37.3%	-102.2M▼ 179.6%	-50.4M▲ 50.7%	-47.95M▲ 0%
Equity Growth %	-	48.14%	124.16%	-1512.7%	37.29%	-179.65%	50.69%	186.88%
Book Value per Share	-4.35	-2.25	0.54	-7.23	-1.42	-2.98	-1.37	-1.33
Total Shareholders' Equity	-32.93M	-17.07M	4.13M	-44.46M	-29.4M	-105.93M	-58.54M	-56.09M
Common Stock	0	0	0	6K	6K	4K	4K	4K
Retained Earnings	-32.9M	-17.05M	4.17M	-44.46M	-29.39M	-100.3M	-49.55M	-46.03M
Treasury Stock	0	0	0	0	0	-5.6M	-8.96M	-10.04M
Accumulated OCI	-33K	-23K	-40K	-5K	-12K	-35K	-29K	-27K
Minority Interest	0	0	0	-13.81M	-7.15M	3.73M	8.14M	8.14M

BTMD Cash Flow Statement

biote Corp. (BTMD) cash flow — operating, investing & free cash flow history

Line item	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	25.35M	26.43M	33.72M	-9.16M	26.88M	45.24M	35.19M	35.19M
Operating CF Margin %	23.05%	22.67%	24.19%	-5.55%	14.5%	22.94%	18.31%	-
Operating CF Growth %	-	4.22%	27.61%	-127.16%	393.58%	68.3%	-22.21%	-116.77%
Net Income	21.29M	29.16M	32.62M	1.32M	3.32M	46K	27.05M	15.6M
Depreciation & Amortization	832K	1.14M	1.4M	2.2M	2.99M	3.57M	3.67M	3.79M
Stock-Based Compensation	0	0	0	82.18M	9.06M	8.73M	8.92M	8.55M
Deferred Taxes	0	0	0	-743K	721K	-2.9M	3.98M	3.26M
Other Non-Cash Items	837K	1.71M	1.16M	-58.3M	19.72M	25.85M	-165K	2.44M
Working Capital Changes	2.4M	-5.59M	-1.46M	-35.81M	-8.93M	9.93M	-8.25M	-3.45M
Change in Receivables	-714K	-1.48M	-752K	-1.56M	-505K	-2.27M	-958K	-147K
Change in Inventory	1.3M	-904K	-5.76M	-1.71M	-6.1M	3.71M	-6.24M	-6.89M
Change in Payables	1.22M	-884K	1.6M	416K	-165K	1.54M	1.01M	4.9M
Cash from Investing	-1.67M	-1.39M	-3.81M	-1.84M	-2.71M	-18.8M	-6.86M	-6.18M
Capital Expenditures	-704K	-295K	-1.45M	-333K	-359K	-6.43M	-5.01M	-3.75M
CapEx % of Revenue	0.64%	0.25%	1.04%	0.2%	0.19%	3.26%	2.61%	-
Acquisitions	0	0	0	0	0	-11.84M	0	0
Investments	-	-	-	-	-	-	-	-
Other Investing	-968K	-1.1M	-2.36M	-1.5M	-2.35M	-526K	-1.85M	-2.44M
Cash from Financing	-13.55M	-18.32M	-20.34M	63.46M	-14.38M	-76.08M	-43.55M	-62.84M
Debt Issued (Net)	44.19M	-5M	-5M	84.38M	-6.25M	-6.25M	-1.25M	313K
Equity Issued (Net)	0	0	0	18K	144K	-5.32M	-3M	-3M
Dividends Paid	-56.63M	-13.32M	-11.4M	-12.89M	-8.69M	-4.74M	-1.73M	-1.03M
Share Repurchases	0	0	0	-424K	0	-5.6M	-3.37M	-4.44M
Other Financing	-1.11M	0	-3.94M	-8.05M	420K	-59.77M	-37.58M	-59.12M
Net Change in Cash	10.12M▲ 0%	6.72M▼ 33.6%	9.56M▲ 42.2%	52.47M▲ 448.9%	9.77M▼ 81.4%	-49.66M▼ 608.2%	-15.22M▲ 69.4%	-36.38M▲ 0%
Free Cash Flow	23.68M▲ 0%	25.03M▲ 5.7%	29.91M▲ 19.5%	-10.99M▼ 136.8%	24.17M▲ 319.8%	38.81M▲ 60.6%	30.18M▼ 22.2%	28.69M▲ 0%
FCF Margin %	21.53%	21.47%	21.46%	-6.67%	13.04%	19.68%	15.7%	15.25%
FCF Growth %	-	5.7%	19.5%	-136.76%	319.83%	60.58%	-22.25%	-22.05%
FCF per Share	3.13	3.30	3.95	-1.36	0.94	1.13	0.82	0.82
FCF Conversion (FCF/Net Income)	1.19x	0.91x	1.03x	9.45x	8.11x	14.33x	1.30x	1.84x
Interest Paid	1.63M	2.49M	1.46M	4.43M	9.48M	9.54M	0	4.03M
Taxes Paid	178K	189K	171K	282K	4.43M	2.59M	0	2.23M

BTMD Key Ratios

biote Corp. (BTMD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	-	790.76%	-	-	-	-	-25.72%
Return on Invested Capital (ROIC)	404.3%	227.68%	-	-	-	1129.32%	1129.32%
Gross Margin	61.46%	64.98%	66.92%	68.78%	70.52%	71.46%	70.12%
Net Margin	25.02%	23.4%	-0.59%	1.79%	1.6%	14.07%	8.29%
Debt / Equity	-	9.05x	-	-	-	-	-2.26x
Interest Coverage	13.10x	20.67x	1.42x	6.09x	1.09x	3.24x	3.02x
FCF Conversion	0.91x	1.03x	9.45x	8.11x	14.33x	1.30x	1.84x
Revenue Growth	5.99%	19.58%	18.34%	12.37%	6.38%	-2.52%	-5.63%

BTMD SEC Filings & Documents

biote Corp. (BTMD) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 6, 2026·SEC

Material company update

Apr 3, 2026·SEC

Material company update

Mar 11, 2026·SEC

10-K Annual Reports

FY 2026

Mar 13, 2026·SEC

FY 2025

Mar 14, 2025·SEC

FY 2024

Mar 15, 2024·SEC

10-Q Quarterly Reports

FY 2025

Nov 7, 2025·SEC

FY 2025

Aug 8, 2025·SEC

FY 2025

May 9, 2025·SEC

BTMD Frequently Asked Questions

biote Corp. (BTMD) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

biote Corp. (BTMD) reported $188.2M in revenue for fiscal year 2025. This represents a 71% increase from $110.0M in 2019.

biote Corp. (BTMD) saw revenue decline by 2.5% over the past year.

Yes, biote Corp. (BTMD) is profitable, generating $15.6M in net income for fiscal year 2025 (14.1% net margin).

Dividend & Returns

Yes, biote Corp. (BTMD) pays a dividend with a yield of 2.25%. This makes it attractive for income-focused investors.

biote Corp. (BTMD) generated $28.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More BTMD

biote Corp. (BTMD) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

biote Corp.(BTMD)Earnings, Financials & Key Ratios

BTMD Key Insights

✓Strengths

✗Weaknesses

BTMD Price & Volume

BTMD Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

BTMD Recent Earnings

BTMD Peer Comparison

Compare BTMD vs Peers

vs HIMS

vs ABBV

Compare Top 5

BTMD Income Statement

BTMD Balance Sheet

BTMD Cash Flow Statement

BTMD Key Ratios

BTMD SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

BTMD Frequently Asked Questions

Explore More BTMD

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation